Moreover, the Non-MAFLD NAFLD participants even have better metabolic status (BMI, waist circumference, insulin, HbA1c, systolic blood pressure, overweight/obesity, Central obesity, Diabetes, Hypertension, Dyslipidemia), CVD outcome (Framingham risk score) and CKD outcome (eGFR) than Non-NAFLD Non-MAFLD participants in both male and female (P<0.05). The gene discussed is INS; the disease is obesity due to melanocortin 4 receptor deficiency.